Gastroenterology

Researchers suggest that patients with chronic hepatitis B virus (HBV) infection who must undergo cancer chemotherapy may avoid reactivation of HBV if they receive prophylaxis with entecavir (Baraclude). If HBV is reactivated because of chemotherapy-related immunosuppression, the patient’s treatment may be complicated by subsequent liver damage, hence the need to keep the virus in check.

CHICAGO | Patients who are scheduled for colonoscopy or polypectomy are often advised to suspend ASA and/or non-steroidal anti-inflammatory drug (NSAID) therapy to reduce the risk of bleeding, but new research presented here suggests that might not be necessary.